RESEARCH DIGEST · THE RECORD
The CJC-1295 Research Record, Logged to Source
Dose-dependent GH and IGF-1 elevation for days, pulsatility preserved beneath the sustained floor, and the bioconjugation mechanism that makes it last — each measured finding tagged by species and evidence tier.
What the GH/IGF-1 Research Shows
The CJC-1295 research record centers on one reproducible result: a single subcutaneous dose raises growth hormone and IGF-1, and keeps them raised for days. In healthy adults, 30 or 60 µg/kg produced dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more, and 1.5- to 3-fold increases in IGF-1 for nine to eleven days [1]. After multiple doses, IGF-1 remained above baseline up to 28 days [1].
A second human study sharpened the single-dose picture. In healthy men aged 20 to 40, one subcutaneous dose of 60 or 90 µg/kg raised trough/basal GH approximately 7.5-fold, mean GH by about 46%, and IGF-1 by about 45% one week later [3]. These are the measured outcomes that anchor every other claim about the compound — not benefits in the marketing sense, but pharmacodynamic readouts in healthy volunteers.
The rationale that draws interest to GHRH analogs in aging research is the somatopause — the age-related decline in GH/IGF-1 axis activity. A 2026 review of therapeutic peptides in gerontology situates GHRH analogs within that longevity-research conversation [15]. The peer-reviewed evidence base in healthy adults, though, remains thin and short-term.
Measured Outcomes in Human PK Studies
The human CJC-1295 results come from early pharmacokinetic studies, and they are precise about what they measured. Teichman and colleagues reported the dose-dependent GH and IGF-1 time courses and the 5.8- to 8.1-day half-life in healthy adults aged 21 to 61 [1]. Ionescu and Frohman reported the +7.5-fold basal GH, +46% mean GH, and +45% IGF-1 figures in healthy young men [3].
A third human study looked at the serum proteome. In 11 healthy young adult men, CJC-1295 administration shifted several serum proteins — decreasing apolipoprotein A1 and a transthyretin isoform, increasing a C-terminal albumin fragment and immunoglobulin species — and the immunoglobulin/albumin-fragment signal correlated linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [5]. The human record is small, but internally consistent: the axis activates, and it stays activated for days.
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs synergize to release more growth hormone together than either alone, and CJC-1295 by itself raised GH and IGF-1 in early human pharmacokinetic studies [1][3]. No controlled efficacy trial of the CJC-1295/ipamorelin combination in healthy adults exists, however, so the literature establishes the two-receptor synergy rationale, not a demonstrated outcome.
What does the research describe?
Early human pharmacokinetic studies described dose-dependent rises in growth hormone and IGF-1 lasting days, with GH pulsatility preserved [1][3]. This is study data in healthy volunteers — a description of measured kinetics, not of effects to expect from non-clinical use.
CJC-1295 and Ipamorelin: The Two-Receptor Rationale
CJC-1295 and ipamorelin are paired in research because they hit two separate receptors. The CJC-1295 ipamorelin combination works through complementary pathways: CJC-1295, a GHRH analog, binds the GHRH receptor on somatotrophs; ipamorelin, a selective GHRP, binds the ghrelin/GHS receptor. Engaging both pathways at once releases more growth hormone than engaging either alone — the mechanistic case for combining a GHRH analog with a GHRP.
What the literature does not provide is a regimen. CJC-1295's own human data come from single- and multiple-dose pharmacokinetic studies of the compound alone [1][3], and the ipamorelin pairing rests on receptor pharmacology rather than on a controlled combination trial in healthy adults. The synergy is real at the mechanism level; the protocols built on it online are not trial-derived.
CJC-1295 Among GHRH Analogs
Questions about CJC-1295 vs sermorelin are really questions about position within one drug class. Sermorelin, CJC-1295, and the FDA-approved tesamorelin are all GHRH analogs acting on the same receptor; what separates them is duration and regulatory status, not mechanism [12]. CJC-1295's distinguishing feature is the DAC-driven multi-day CJC-1295 half-life, against sermorelin's short action — but no head-to-head trial in healthy adults supports a direct efficacy comparison, so this site positions CJC-1295 within the class rather than asserting a winner.
The Mechanism and the Preclinical Evidence
Mechanistically, CJC-1295 binds the GHRH receptor, a class B GPCR, activating Gs/cAMP/PKA signaling that drives CREB-dependent GH gene transcription; the released GH then acts on hepatic GH receptors via JAK2/STAT5 to produce IGF-1 [1]. The DAC modification adds a layer to that picture — covalent albumin binding extends plasma residence, giving sustained GHRH-receptor stimulation from a single dose.
The preclinical record built the case before the human studies. A screen of hGRF(1-29)-albumin bioconjugates identified CJC-1295 as the lead long-acting analog: it combined four DPP-IV-protective substitutions with covalent serum-albumin conjugation, showed a 4-fold GH AUC increase over two hours versus unconjugated hGRF(1-29) in rats, remained detectable in plasma beyond 72 hours, and was stable against DPP-IV in vitro [2].
In GHRH-knockout mice, 2 µg of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective; treatment also increased pituitary GH mRNA [4]. That result is the clearest demonstration that the long-acting analog's once-daily schedule is sufficient to restore GH-axis-dependent growth. Related GHRH-class work — agonist analogs promoting wound healing [10] and a GHRH-expression plasmid improving bone and skin endpoints in aged mice [11] — illustrates tissue-level effects studied across the analog class, though these used different molecules and models.
Pulsatility Preserved, and Why It Matters
A notable feature of CJC-1295 is that it sustains GH output without flattening the natural pulse pattern. In the healthy-men study, the frequency and magnitude of pulsatile GH secretion were unaltered even under continuous GHRH-analog stimulation [3]. Growth hormone is normally secreted in episodic pulses, and the finding that pulsatility persists beneath an elevated baseline distinguishes a GHRH analog from a continuous GH infusion.
The compound's footprint in the analytical and anti-doping literature is, by contrast, substantial. CJC-1295 was structurally identified by high-resolution LC-MS/MS as the active ingredient in an unknown 'GHRH' preparation seized in an anti-doping context [6]. Confirmatory methods have since multiplied: immunoaffinity-MS identification of GHRH analogs in human plasma [9], an antibody-free ultrafiltration-based assay [7], reviews of GHRH-analog detection [8], a 2024 chromatographic-MS method for 2-10 kDa peptidic analytes [13], and a 2025 nano-LC-MS urinary method [14]. The detection science around CJC-1295 is well developed precisely because the compound is prohibited in sport.